Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia
Abstract
Objectives: To assess the diagnostic specificity of MRI-defined hippocampal atrophy for AD among individuals with a variety of pathologically confirmed conditions associated with dementia as well as changes attributable to typical aging, and to measure correlations among premortem MRI measurements of hippocampal atrophy, mental status examination performance, and the pathologic stage of AD.
Methods: An unselected series of 67 individuals participating in the Mayo Alzheimer’s Disease Research Center/Alzheimer’s Disease Patient Registry who had undergone a standardized antemortem MRI study and also postmortem examination were identified. Hippocampal volumes were measured from antemortem MRI. Each postmortem specimen was assigned a pathologic diagnosis and in addition, the severity of AD pathology was staged using the method of Braak and Braak.
Results: Individuals with an isolated pathologic diagnosis of AD, hippocampal sclerosis, frontotemporal degeneration, and neurofibrillary tangle–only degeneration usually had substantial hippocampal atrophy, while those with changes of typical aging did not. Among all 67 subjects, correlations (all p < 0.001) were observed between hippocampal volume and Braak and Braak stage (r = −0.39), between hippocampal volume and Mini-Mental State Examination (MMSE) score (r = 0.60), and between MMSE score and Braak and Braak stage (r = −0.41).
Conclusions: Hippocampal atrophy, while not specific for AD, was a fairly sensitive marker of the pathologic AD stage (particularly among subjects with isolated AD pathology [r = −0.63, p = 0.001]) and consequent cognitive status.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol . 1991; 82: 239–259.
2.
Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. Neurobiol Aging 1997;18:S1–S2.
3.
de Leon MJ, Golomb J, Convit A, et al. Measurement of medial temporal lobe atrophy in diagnosis of Alzheimer’s disease. Lancet . 1993; 341: 125.Letter.
4.
Fox NC, Warrington EK, Freeborough PA, et al. Presymptomatic hippocampal atrophy in Alzheimer’s disease. A longitudinal MRI study. Brain . 1996; 119: 2001–2007.
5.
Jack CR Jr, Petersen RC, O’Brien PC, et al. MR-based hippocampal volumetry in the diagnosis of Alzheimer’s disease. Neurology . 1992; 42: 183–188.
6.
Jobst KA, Smith AD, Szatmari M, et al. Rapidly progressing atrophy of medial temporal lobe in Alzheimer’s disease. Lancet . 1994; 343: 829–830.
7.
Juottonen K, Laakso P, Insausti R, et al. Volumes of the entorhinal and perirhinal cortices in Alzheimer’s disease. Neurobiol Aging . 1998; 19: 15–22.
8.
Laakso MP, Soininen H, Partanen K, et al. Volumes of hippocampus, amygdala and frontal lobes in the MRI-based diagnosis of early Alzheimer’s disease: correlation with memory functions. J Neural Transm . 1995; 9: 73–86.
9.
Petersen RC, Jack CR Jr, Xu YC, et al. Memory and MRI-based hippocampal volumes in aging and Alzheimer’s disease. Neurology . 2000; 54: 581–587.
10.
Jack CR Jr, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer’s disease. Neurology . 1997; 49: 786–794.
11.
Petersen RC, Kokmen E, Tangalos EG, et al. Mayo Clinic Alzheimer’s Disease Patient Registry. Aging . 1990; 2: 408–415.
12.
Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, et al. Apolipoprotein E status as a predictor of the development of Alzheimer’s disease in memory impaired individuals. JAMA . 1995; 273: 1274–1278.
13.
Smith GE, Petersen RC, Parisi JE, et al. Definition, course, and outcome of mild cognitive impairment. Aging Cogn Neuropsychol . 1996; 3: 141–147.
14.
Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association, 1987.
15.
Ivnik RJ, Malec JF, Smith GE, et al. Mayo’s older Americans normative studies: WAIS-R, WMS-R, and AVLT norms for ages 56 through 97. Clin Neuropsychol . 1992; 6: 1–103.
16.
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment clinical characterization and outcome. Arch Neurol . 1999; 56: 303–308.
17.
Jack CR Jr, Petersen RC, Xu Y, et al. The rate of medial temporal lobe atrophy in typical aging and Alzheimer’s disease. Neurology . 1998; 51: 993–999.
18.
Gwinn-Hardy K, Mehta N, Farrer M, et al. Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary Parkinsonism and dementia linked to chromosome 4p. Acta Neuropathol . 2000; 99: 663–672.
19.
Dickson D, Wertkin A, Kress Y, Ksiezak-Reding H, Yen S-H. Ubiquitin-immunoreactive structures in normal brains: distribution and developmental aspects. Lab Invest . 1990; 63: 87–99.
20.
Dickson D, Yen S-H. Ubiquitin, the cytoskeleton and neurodegenerative diseases. In: Mayer RJ, Brown IR, eds. Heat shock or stress proteins and the nervous system. London: Academic Press, 1994: 235–262.
21.
McKeith IG, Galasko D, Kosaka K, et al. Clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on Dementia with Lewy Bodies International Workshop. Neurology . 1996; 47: 1113–1124.
22.
Dickson DW, Davies P, Bevona C, et al. Hippocampal sclerosis: a common pathological feature of dementia in very old (greater than 80 years of age) humans. Acta Neuropathol . 1994; 88: 212–221.
23.
Brun A, England B, Gustafson L, Passant U, et al. Clinical and neuropathological criteria for frontotemporal dementia: The Lund and Manchester groups. J Neurol Neurosurg Psychiatry . 1994; 57: 416–418.
24.
Jellinger KA, Bancher C. Senile dementia with tangles (tangle predominant form of senile dementia). Brain Pathol . 1998; 8: 367–376.
25.
Vinters HV, Ellis WG, Zabrow C, et al. Neuropathologic substrates of ischemic vascular dementia. J Neuropathol Exp Neurol . 2000; 59: 931–945.
26.
Grober E, Dickson D, Sliwinski MJ, et al. Memory and mental status correlates of modified Braak staging. Neurobiol Aging . 1999; 20: 573–579.
27.
Braak H, Braak E, Bohl J. Staging of Alzheimer-related cortical destruction. Eur Neurol . 1993; 33: 403–408.
28.
Maunoury C, Michot J-L, Caillet H, et al. Specificity of temporal amygdala atrophy in Alzheimer’s disease: quantitative assessment with magnetic resonance imaging. Dementia . 1996; 7: 10–14.
29.
Laakso MP, Partanen K, Riekkinen P, et al. Hippocampal volumes in Alzheimer’s disease, Parkinson’s disease with and without dementia, and in vascular dementia: an MRI study. Neurology . 1996; 46: 678–681.
30.
Smith AD, Jobst KA. Use of structural imaging to study the progression of Alzheimer’s disease. Br Med Bull . 1996; 52: 575–586.
31.
Davis PC, Gray L, Albert M, et al. The consortium to establish a registry for Alzheimer’s disease (CERAD). Part III. Reliability of a standardized MRI evaluation of Alzheimer’s disease. Neurology . 1992; 42: 1676–1680.
32.
Riekkinen P, Kejonen K, Laakso MP, Soininen H, Partanen K, Riekkinen M. Hippocampal atrophy is related to impaired memory, but not frontal functions in non-demented Parkinson’s disease patients. Neuroreport . 1998; 9: 1507–1511.
33.
Nagy Z, Hindley NJ, Braak H, et al. Relationship between clinical and radiological diagnostic criteria for Alzheimer’s disease and the extent of neuropathology as reflected by stages: a prospective study. Dement Geriatr Cogn Disord . 1999; 10: 109–114.
34.
Nagy Z, Hindley NJ, Braak H, et al. The progression of Alzheimer’s disease from limbic regions to the neocortex: clinical, radiological and pathological relationships. Dement Geriatr Cogn Disord . 1999; 10: 115–120.
35.
Holodny AI, Waxman R, George AE, Rusinek H, Kalmin AJ, de Leon M. MR differential diagnosis of normal-pressure hydrocephalus and Alzheimer disease: significance of perihippocampal fissures. AJNR Am J Neuroradiol . 1998; 19: 813–819.
36.
Jack CR Jr, Rydberg CH, Krecke KN, et al. Mesial temporal sclerosis: diagnosis with fluid-attenuated inversion-recovery versus spin-echo MR Imaging. Radiology . 1996; 199: 367–373.
37.
Jack CR Jr, Sharbrough FW, Twomey CK, et al. Temporal lobe seizures: lateralization with MR volume measurements of hippocampal formation. Radiology . 1990; 175: 423–429.
38.
Campeau NG, Petersen RC, Felmlee JP, et al. Hippocampal transverse relaxation time (T2) measurements in patients with Alzheimer’s disease and in elderly nondemented controls. Radiology . 1997; 205: 197–201.
39.
Lippa C, Johnson R, Smith T. The medial temporal lobe in dementia with Lewy bodies: a comparative study with Alzheimer’s disease. Ann Neurol . 1998; 43: 102–106.
40.
O’Brien J, Paling S, Barber R, et al. Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology . 2001; 56: 1386–1388.
41.
Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques, and related immunohistochemical markers in healthy aging and Alzheimer’s disease. Neurobiol Aging . 1991; 12: 295–312.
42.
Davis D, Schmitt F, Wekstein D, Markesbery W. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol . 1999; 58: 376–388.
43.
Morris J, Storandt M, MeKeel D, et al. Cerebral amyloid deposition and diffuse plaques in ‘normal‘ aging: evidence for presymptomatic and very mild Alzheimer’s disease. Neurology . 1996; 46: 707–719.
44.
Green M, Kaye J, Ball M. The Oregon Brain Aging Study. Neurology . 2000; 54: 105–113.
45.
Bobinski M, deLeon MJ, Wegiel J, Desanti S, et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer’s disease. Neuroscience . 2000; 95: 721–725.
Information & Authors
Information
Published In
Copyright
© 2002.
Publication History
Received: May 16, 2001
Accepted: November 19, 2001
Published online: March 12, 2002
Published in print: March 12, 2002
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Classifying Alzheimer’s Disease Neuropathology Using Clinical and MRI Measurements, Journal of Alzheimer's Disease, 100, 3, (843-862), (2024).https://doi.org/10.3233/JAD-231321
- Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer’s disease, Translational Neurodegeneration, 13, 1, (2024).https://doi.org/10.1186/s40035-024-00417-w
- Delivering synaptic protein mRNAs via extracellular vesicles ameliorates cognitive impairment in a mouse model of Alzheimer’s disease, BMC Medicine, 22, 1, (2024).https://doi.org/10.1186/s12916-024-03359-2
- Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults, BMJ Open, 14, 6, (e081401), (2024).https://doi.org/10.1136/bmjopen-2023-081401
- CirMNet: A Shape-Based Hybrid Feature Extraction Technique Using CNN and CMSMD for Alzheimer’s MRI Classification, IEEE Access, 12, (80491-80504), (2024).https://doi.org/10.1109/ACCESS.2024.3408311
- Cross-Modality Image Translation From Brain 18F-FDG PET/CT Images to Fluid-Attenuated Inversion Recovery Images Using the CypixGAN Framework, Clinical Nuclear Medicine, 49, 11, (e557-e565), (2024).https://doi.org/10.1097/RLU.0000000000005441
- Memory impairment in Amyloidβ-status Alzheimer's disease is associated with a reduction in CA1 and dentate gyrus volume: In vivo MRI at 7T, NeuroImage, 292, (120607), (2024).https://doi.org/10.1016/j.neuroimage.2024.120607
- Early rise of glutamate-glutamine levels in mild cognitive impairment: Evidence for emerging excitotoxicity, Journal of Neuroradiology, 51, 2, (168-175), (2024).https://doi.org/10.1016/j.neurad.2023.09.003
- Alzheimer disease (AD) medical image analysis with convolutional neural networks, Intelligent Fractal-Based Image Analysis, (197-230), (2024).https://doi.org/10.1016/B978-0-44-318468-0.00017-9
- IG-GRD: A Model Based on Disentangled Graph Representation Learning for Imaging Genetic Data Fusion, Advanced Intelligent Computing Technology and Applications, (142-153), (2024).https://doi.org/10.1007/978-981-97-5581-3_12
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.